On April 17, 2024, Ruiang Gene disclosed in its annual report that the number of shareholders of the company as of March 31, 2024 was 4,233, a decrease of 1,084 or 20.39% from the previous period (December 31, 2023).
The number of shareholders of Ruiang Gene is lower than the industry average. According to Choice data, as of March 31, 2024, the average number of shareholders of listed companies in the pharmaceutical and biotechnology industry is 34,500. Among them, the number of shareholders of the company is in the range of 5,000~15,000, accounting for the highest proportion, 29.88%.
Distribution of the number of shareholders in the pharmaceutical and biological industry
Number of shareholders and share price
Since March 31, 2023, the number of shareholders of the company has decreased, with a decrease of 2.98%. From March 31, 2023 to March 31, 2024, the stock price decreased by 38.63%.
Number of shareholders and share price
Number of shareholders and share capital
As of March 31, 2024, the company's latest total share capital is 55,855,900 shares, of which the outstanding share capital is 37,504,500 shares. The average number of outstanding shares held by households increased from 7,054 shares in the previous period to 8,860 shares, and the average market value of households was 244,000 yuan.
The average amount of shares held by each household
The market value of circulating accounts held by Ruiang Gene is lower than the industry average. According to Choice data, as of March 31, 2024, the average market value of A-share listed companies in the pharmaceutical and biological industry was 415,300 yuan. Among them, 24.69% of the company's households hold a circulating stock market value of 140,000~270,000 yuan, and Ruiang Gene is also in the range.
Distribution of per capita circulating market value of the pharmaceutical and biological industry
Disclaimer: This article is based on big data and is for reference only and does not constitute any investment advice.